Search results for aptivus

Boehringer Ingelheim announced that the European Commission has given the full marketing authorisation to its HIV protease inhibitor (PI), Aptivus® (tipranavir). The Commission has fully approved Apt read more »
Discuss   Add this link to...  Bury